GENE ONLINE|News &
Opinion
Blog

bluebird bio
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
Bluebird’s Rare Childhood Neurodegenerative Gene Therapy Gains Accelerated Approval
2022-09-19
Bluebird Bio’s Zynteglo Becomes First FDA-Approved Gene Therapy For Beta-Thalassemia
2022-08-18
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
FDA Grants Priority Review for bluebird bio’s β-Thalassemia Gene Therapy
2021-11-23
Resilience Acquires Bluebird Bio’s Manufacturing Facility to Develop Next Gen Cell Therapies
2021-07-31
BMS, bluebird’s Multiple Myeloma Drug Becomes First BCMA Targeting CAR-T Therapy to Snag FDA Okay
2021-03-28
Bluebird Bio Temporarily Suspends Sickle Cell Trials Following Cancer Diagnosis in Two Patients
2021-02-18
BMS, bluebird bio’s Investigational BCMA CAR-T Therapy Faces Regulatory Setback
2020-05-18
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top